Overview: Fibroblast Growth Factor 2 (FGF2) TestIntroduction: The Fibroblast Growth Factor 2 (FGF2) Test measures FGF2 levels to assess tissue repair or cancer growth, causing abnormal lumps. Aligned with 2023 ASCO guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected cancer or tissue repair issues.
Other Names: FGF2 Assay, Basic FGF Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: FGF2 testing began in the 1990s with cancer and tissue repair research. Immunoassays emerged in the 2000s, improving accuracy for growth factor detection.
Purpose: Diagnoses cancer or tissue repair issues, guides treatment, and monitors FGF2 levels in patients with abnormal lumps.
Test Parameters: 1. Fibroblast Growth Factor 2
Pretest Condition: Fasting for 10-12 hours required to stabilize results. Collect serum or plasma in the morning. Report symptoms like abnormal lumps, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document abnormal lumps or history of cancer/tissue repair issues. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses an immunoassay to measure FGF2 levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting or medications can affect results. Hemolysis may degrade samples.
Clinical Significance: Elevated FGF2 levels suggest cancer or active tissue repair, prompting further evaluation. Normal levels may require additional testing.
Specialist Consultation: Consult an oncologist for result interpretation.
Additional Supporting Tests: Imaging, biopsy, or tumor markers to confirm cancer or tissue repair status.
Test Limitations: Non-specific elevations may occur in non-cancer conditions. Results require clinical correlation.
References: ASCO Cancer Guidelines, 2023; Clinical Cancer Research, Turner N, 2022.
